# INDONESIAN JOURNAL OF Clinical Pathology and Medical Laboratory

Majalah Patologi Klinik Indonesia dan Laboratorium Medik



Published by Indonesian Association of Clinical Pathologists

Accredited No. 36a/E/KPT/2016, Tanggal 23 Mei 2016

## **INDONESIAN JOURNAL OF**

## CLINICAL PATHOLOGY AND MEDICAL LABORATORY

Majalah Patologi Klinik Indonesia dan Laboratorium Medik

## **EDITORIAL TEAM**

Editor-in-chief: Puspa Wardhani

## Editor-in-chief Emeritus:

Prihatini Krisnowati

### **Editorial Boards:**

Maimun Zulhaidah Arthamin, Rahayuningsih Dharma, Mansyur Arif, July Kumalawati, Nurhayana Sennang Andi Nanggung, Aryati, Purwanto AP, Jusak Nugraha, Sidarti Soehita, Endang Retnowati Kusumowidagdo, Edi Widjajanto, Budi Mulyono, Adi Koesoema Aman, Uleng Bahrun, Ninik Sukartini, Kusworini Handono, Rismawati Yaswir, Osman Sianipar

**Editorial Assistant:** 

Dian Wahyu Utami

Language Editors: Yolanda Probohoesodo, Nurul Fitri Hapsari

> Layout Editor: Akbar Fahmi

**Editorial Adress:** 

d/a Laboratorium Patologi Klinik RSUD Dr. Soetomo, Gedung Diagnostik Center Lt. IV Jl. Mayjend. Prof. Dr Moestopo 6–8 Surabaya, Indonesia Telp/Fax. (031) 5042113, 085-733220600 E-mail: majalah.ijcp@yahoo.com, jurnal.ijcp@gmail.com Website: http://www.indonesianjournalofclinicalpathology.or.id

Accredited No. 36a/E/KPT/2016, Tanggal 23 Mei 2016

## **INDONESIAN JOURNAL OF**

## CLINICAL PATHOLOGY AND MEDICAL LABORATORY

Majalah Patologi Klinik Indonesia dan Laboratorium Medik

## CONTENTS

#### RESEARCH

Leukocyte Interference on Hemoglobin Examination in Hematology Malignancy	
(Pengaruh Jumlah Leukosit terhadap Kadar Hemoglobin pada Keganasan Hematologi)	
Trinil Sulamit, Fery H. Soedewo, Arifoel Hajat	203–207
The Analysis of Calcium Level in Stored Packed Red Cells	
(Analisa Kadar Kalsium Darah Simpan Packed Red Cells)	
Suryani Jamal, Rachmawati Muhiddin, Mansyur Arif	208–210
Correlation between Matrix Metalloproteinase 1 Serum Levels and Model of End Stage Liver Disease	
Score in Patients with Hepatic Cirrhosis	
(Kenasaban Kadar Matrix Metalloproteinase 1 Serum Terhadap Skor Model End Stage Liver Disease di	
Pasien Sirosis Hati)	
Stephanus Yoanito, Siti Muchayat	211–215
Relationship between D-Dimer Level and Clinical Severity of Sepsis	
(Hubungan antara Kadar D-dimer dan Tingkat Keparahan Klinis di Sepsis)	
Yessy Puspitasari, Aryati, Arifoel Hajat, Bambang Pujo Semedi	216–220
Comparison of Factor VIII Activity in O and Non-O Blood Types	
(Perbandingan Aktivitas Faktor VIII Antara Golongan Darah O dan Non-O)	
Adil Dinata Simangunsong, Yetti Hernaningsih	221–224
Apo B/Apo A-I Ratio in Patients with Stenosis Coronary Heart Disease Greater or Less than 70%	
(Rasio Apo B/Apo A-I di Pasien Penyakit Jantung Koroner dengan Stenosis Lebih Besar Atau Kecil 70%)	
Dedi Ansyari, Tapisari Tambunan, Harris Hasan	225–229
Analysis of Dengue Specific Immune Response Based on Serotype, Type and Severity of Dengue Infection	
(Analisis Respons Imun Spesifik Dengue terhadap Serotipe, Jenis dan Derajat Infeksi Virus Dengue)	
Ade Rochaeni, Aryati Puspa Wardhani, Usman Hadi	230–233
Neutrophil/Lymphocyte Count Ratio on Dengue Hemorrhagic Fever	
(Rasio Netrofil/Limfosit Pada Demam Berdarah Dengue)	
Irmayanti, Asvin Nurulita, Nurhayana Sennang	234–239
Neutrophil-Lymphocyte Ratio and High Sensitivity C-Reactive Protein as Ischemic Stroke Outcome	
Predictor	
(Rasio Neutrofil–Limfosit dan High Sensitivity C–Reactive Protein sebagai Peramal Hasilan Strok	
Iskemik Akut)	
Tissi Liskawini Putri, Ratna Akbari Ganie, Aldy S. Rambe	240–245
Analysis of Rhesus and Kell Genotype in Patients with Transfusion Reaction	
(Analisis Genotipe Rhesus dan Kell Pasien dengan Reaksi Transfusi)	0.46 075
Sukmawaty, Kachmawati Muhiddin, Mansyur Arif	246–250

Printed by Airlangga University Press. (OC 252/08.17/AUP-A1E). E-mail: aup.unair@gmail.com Kesalahan penulisan (isi) di luar tanggung jawab AUP

	Diagnostic Value of Fastsure TB DNA Rapid Test for Diagnosis of Pulmonary Tuberculosis (Nilai Diagnostik dari Uji Cepat Fastsure TB DNA untuk Diagnosis Tuberkulosis Paru) <b>Diyan Wahyu Kurniasari, Jusak Nugraha, Aryati</b>	251–256
	Neutrophil-Lymphocyte Count Ratio in Bacterial Sepsis (Rasio Neutrofil-Limfosit Pada Sepsis Bakterial) <b>Danny Luhulima, Marwito, Eva O</b>	257–262
	Comparison of Percentage Peripheral Blood Lymphoblast Proliferation and Apoptosis in Pediatric Acute Lymphoblastic Leukemia Before and After Chemotherapy Induction Phase (Perbandingan Persentase Proliferasi dan Apoptosis Limfoblas di Darah Tepi di Pasien Leukemia Limfoblastik Akut Anak Sebelum dan Sesudah Kemoterapi Tahap Induksi) Farida Nur'Aini, Endang Retnowati, Yetti Hernaningsih, Mia Ratwita A	263–268
	Analysis of Erythrocyte Indices in Stored Packed Red Cells at The Blood Bank of Dr. Wahidin Sudirohusodo Hospital (Analisis Indeks Eritrosit Darah Simpan Packed Red Cells di Bank Darah RSUP Dr. Wahidin Sudirohusodo Makassar) Fitrie Octavia, Rachmawati Muhiddin, Mansyur Arif	269–274
	Correlation of Urine N-Acetyl-Beta-D-Glucosaminidase Activity with Urine Albumin Creatinine Ratio in Type 2 Diabetes Mellitus ( <i>Kenasaban Aktivitas N-Asetil-Beta-D-Glukosaminidase Air Kemih dengan Air Kemih Albumin Kreatinin</i> <i>Rasio di Diabetes Melitus Tipe 2</i> ) <b>Melly Ariyanti, Lillah, Ellyza Nasrul, Husni</b>	275–280
	Agreement of Simplified Fencl-Stewart with Figge-Stewart Method in Diagnosing Metabolic Acidosis in Critically Ill Patients ( <i>Kesesuaian Metode Fencl-Stewart yang Disederhanakan dengan Figge-Stewart dalam Mendiagnosis</i> <i>Asidosis Metabolik di Pasien Critically Ill</i> ) <b>Reni Lenggogeni, Rismawati Yaswir, Efrida, Desywar</b>	281–286
	Comparison of Peripheral Blood Activated NK Cell Percentage Before and After Induction Phase Chemotherapy in Pediatric Acute Lymphoblastic Leukemia (Perbandingan Persentase Sel NK Teraktivasi Darah Tepi Sebelum dan Sesudah Kemoterapi Tahap Induksi di Pasien Leukemia Limfoblastik Akut Anak) Syntia TJ, Endang Retnowati, Yetti Hernaningsih, I Dewa Gede Ugrasena, Soeprapto Ma'at	287–293
LIT	ERATURE REVIEW	
	Quality of Stored Red Blood Cells (Kualitas Sel Darah Merah Simpan) <b>Anak Agung Wiradewi Lestari, Teguh Triyono, Usi Sukoroni</b>	294–302
CAS	SE REPORT	
	A Thirty-One-Years-Old Female with SLE and Systemic Scleroderma (Perempuan Usia 31 Tahun dengan SLE dan Skleroderma Sistemik) Rahardjo, Rachmawati	303–309

## Thanks to editors in duty of IJCP & ML Vol 23 No. 3 July 2017

Rismawati Yaswir, Nurhayana Sennang Andi Nanggung, Adi Koesoema Aman, Osman sianipar, Purwanto AP, Budi Mulyono, Jusak Nugraha, Rahajuningsih Dharma INDONESIAN JOURNAL OF

## CLINICAL PATHOLOGY AND MEDICAL LABORATORY

Majalah Patologi Klinik Indonesia dan Laboratorium Medik

## RESEARCH

## CORRELATION BETWEEN MATRIX METALLOPROTEINASE 1 SERUM LEVELS AND MODEL OF END STAGE HEPATIC DISEASE SCORE IN PATIENTS WITH HEPATIC CIRRHOSIS

(Kenasaban Kadar Matrix Metalloproteinase 1 Serum terhadap Skor Model End Stage Hepatic Disease di Pasien Sirosis Hati)

Stephanus Yoanito, Siti Muchayat

#### ABSTRAK

Sirosis hati masih menjadi masalah kesehatan utama di dunia, merupakan penyakit fibrosis hati yang berkebahayaan komplikasi. Pemeriksaan biopsi hati masih merupakan baku emas dalam penegakan diagnosis sirosis hati, tetapi pemeriksaan ini bersifat menyakitkan. Banyak model prognostik telah dikembangkan dalam dua dekade terakhir untuk meramalkan kematian di pasien sirosis hati dan variabel yang termasuk dalam model ini adalah Model End Stage Hepatic Disease (MELD). Penelitian ini mengukur kadar Matrix Metalloproteinase 1 (MMP-1) serum sebagai enzim dalam proses degradasi matrix extraselular pada sirosis hati, yang dapat digunakan untuk menilai tingkat keparahan di pasien sirosis hati. Tujuan penelitian ini adalah mengetahui korelasi kadar MMP-1 serum terhadap skor MELD di pasien sirosis hati. Penelitian ini menggunakan rancangan observasional potong lintang. Ciri subjek ditampilkan secara deskriptif dalam perbandingan. Ciri hasil laboratorium dalam bentuk rerata, simpang baku, median (minimum-maksimum). Uji Spearman digunakan untuk mengetahui kenasaban kadar MMP-1 serum terhadap skor MELD di pasien sirosis hati. Sebanyak 30 pasien sirosis hati, rerata umur 52,43 tahun, dominasi laki-laki sebesar 19 pasien (63,3%), penyebab terbanyak adalah HBV sebesar 18 pasien (60,4%), dengan nilai median skor MELD adalah 15,5 dan kadar rerata MMP-1 adalah 106,91 pg/mL. Terdapat kenasaban negatif moderate antara kadar MMP-1 serum dengan skor MELD di pasien sirosis hati. Untuk aplikasi klinis pemeriksaan MMP-1 serum dapat digunakan untuk memantau hasil pengobatan dan perjalanan penyakit pasien sirosis hati.

Kata kunci: Matrix metalloproteinase-1, skor MELD, sirosis hati

#### ABSTRACT

Hepatic cirrhosis is still a major health problem in the world and it has a great risk of complications. Hepatic biopsy is still the gold standard to diagnose hepatic cirrhosis, but it is invasive. Many prognostic models have been developed in the last two decades to predict mortality in patients with hepatic cirrhosis is Model End Stage Hepatic Disease (MELD). This study measured the levels of Matrix Metalloproteinase-1 (MMP-1) serum as the enzyme of extracellular matrix degradation process in hepatic cirrhosis that can be used to assess the severity of hepatic cirrhosis patients. The purpose of this study was to assess the correlation of levels of MMP-1 serum to MELD score in patients with hepatic cirrhosis. This study was a cross-sectional observational design. Subjects characteristics were presented descriptively in the proportions. Laboratory results characteristics were presented in mean, standard deviations, median (minimum and maximum). Spearman correlation was used to correlate the serum levels of MMP-1 to the MELD score in patients (63.3%), HBV was the most common cause of 18 patients (60.4%), with a median MELD score was 15.5 and the average level of MMP-1 was 106.91 mg/mL. A moderate negative correlation between serum levels of MMP-1 with MELD scores, r=-0.402 (p=0.028) was found. The presence of a moderate negative and significant correlation between serum levels of MMP-1 with MELD scores in patients with hepatic cirrhosis was found. For clinical application, examination of serum MMP-1 can be used to monitor disease progression and treatment outcomes of patients with hepatic cirrhosis.

Key words: Matrix metalloproteinase-1, MELD scores, hepatic cirrhosis

Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, University of Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia. E-mail: yoyo\_redmio@yahoo.co.id

## INTRODUCTION

Hepatic cirrhosis and chronic hepatic disease are the 12<sup>th</sup> leading cause of death in the United States, in 2002, as many as 27.257 deaths (9.5 per 100,000 population) were reported, especially regarding males. In 2002, the World Health Organization (WHO), estimated that 783.000 patients in the world died from hepatic cirrhosis.<sup>1</sup> In Indonesia, data on the prevalence of hepatic cirrhosis nationally has not yet been reported, only reports of some education centers exist. The number of patients with hepatic cirrhosis in the Dr. Sardjito Hospital ranges from 4.1% per year out of the patients treated in the Department of Internal Medicine in the period from January to December 2002 were 301 cirrhosis hepatis patients.<sup>2</sup>

The prevalence of chronic HBV infection is more than 1% of the population in the world, with an estimated 300 million carriers. Infected hepatitis C Virus is about 100–300 million people in the world, approximately 20–25% of chronic hepatitis C become hepatic cirrhosis after a period of 10–20 years, while the prevalence of patients with hepatic fibrosis in the United States an estimated 360 patients per 100,000 people.<sup>3</sup>

Cirrhosis of the hepatic is defined as the final stages of hepatic fibrosis consequences which resulted in the formation of abnormal nodules and can alter hepatic function. Various etiological factors associated with chronic hepatitis among HBV or HCV, parasites, alcoholism, metabolic disorders for example  $\alpha$ 1-antitrypsin, ceruloplasmin deficiency, cystic fibrosis, autoimmune and drug intoxication.<sup>4</sup>

Examination of hepatic biopsy is still the gold standard in the diagnosis of hepatic cirrhosis. However, these tests are invasive, costly, need a have long time and frequent complications. Many prognostic models have been developed in the last two decades to predict mortality in patients with hepatic cirrhosis.

Model End Stage Hepatic Disease Score can be used to predict patients who will undergo Transjugular Intrahepatic Portosystemic Shunt (TIPS) therapy, as a tool for determining the priority of patients on waiting list who underwent hepatic transplantation/selected patients who will undergo a hepatic transplant and as a predictive factor deterioration of hepatic function and risk prediction mortality in cirrhotic patients.<sup>5-7</sup>

MELD score is composed of 3 bilirubin laboratory parameters, namely, the International Normalized Ratio (INR) and creatinine. MELD score is objective, all the parameters obtained from laboratory tests and are widely available, but it still takes some parameters into account and has some limitations.

Research on various parameters related to cirrhosis of the hepatic keeps continuing.<sup>8</sup> Definition of hepatic cirrhosis is morphologically characterized by diffuse fibrosis and conversion process of normal architecture of the hepatic becoming abnormal nodules structure. Hepatocyte necrosis and inflammation are chronic recurrent results in changes of hepatocytes enzymes, including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) which is in blood; disruption to the metabolism of carbohydrates, proteins such as albumin and coagulation factor proteins and fats. Cytokines, chemokines of hepatocytes, biliary duct epithelial cells and leukocyte activation of HSC undergo transdifferentiation into myofibroblast changes in expression and secretion of extracellular matrix and deposition of extracellular matrix in between collagen.<sup>8-10</sup> Degradation of collagen is controlled by MMPs and tissue inhibitors inhibited by metalloproteinases matrix (TIMPs) and the increase in violent collagen serum levels is controlled.<sup>11</sup> TIMP-1 and TIMP-1/MMP-1 can be used as an index diagnosis of hepatic fibrosis in chronic hepatitis B virus infection. Role of TGF-ß1, TIMP-1 and MMP-1 and the ratio of MMP/TIMP as biomarker predictors of progression of chronic hepatitis activity and was supported by this current research.<sup>11,12</sup>

One of the genetic factors MMP-1 gene polymorphism as a key to decrease MMP-1 in hepatic cirrhosis, is the interaction of environmental factors with genetic variations in the progression of hepatic fibrosis research. Okamoto *et al.*<sup>13</sup> on MMP-1 gene polymorphisms 1G/2G, MMP-3 5A/6A, MMP-9 C/T found that matrix metalloproteinase have important role in the progression of hepatic fibrosis.<sup>13</sup>

This study aimed to investigate the correlation between the levels of Matrix Metalloproteinase-1 (MMP-1) serum with MELD score in patients with hepatic cirrhosis.

#### **METHODS**

This study design was a cross-sectional observational, performed in the Medicine wards, Gastro-Hepatology Clinic of the Dr. Sardjito Hospital and Clinical Laboratory, Dr. Sardjito Hospital, Yogyakarta for 12 months. Inclusion criteria were patients with cirrhosis of the hepatic with ultrasound diagnosis by clinicians who are hospitalized in the Internal Medicine ward and outpatient clinic of Gastro-Hepatology Dr. Sardjito Hospital, adult patients and who signed an informed consent. Exclusion criteria were patients with cirrhosis of the hepatic accompanied by other diseases such as Diabetes Mellitus (DM), Chronic Kidney Disease (CKD), alcohol use in the last 2 weeks, gastrointestinal bleeding or blood transfusion in the last 2 weeks. Examination of MMP-1 is done by using ELISA method. Bilirubin measurements were performed by Diazo method. In this method, bilirubin reacts with Diazo reagent, assisted by caffeine, benzoate and acetate as accelerators, forming azobilirubin blue. The colour change was measured by a spectrophotometer at a wavelength of 520 nm. The normal value of total bilirubin is <1.1 mg/dL.

Creatinine measurement was done by Jaffe, it is creatinine in solution form the compound picric alkaline red yellow colour intensity can be measured by photometry. The normal value of creatinine for males is <1.2 mg/dL and for females is <0.9 mg/dL.

The principle of partial Prothrombin Time (PPT) was that  $Ca^{2+}$  ions in the blood are bound by an anticoagulant to prevent clotting. Plasma containing all the extrinsic coagulation factors (F.VII,  $Ca^{2+}$ ) and common pathway (F.X, F.V, prothrombin and fibrinogen) except  $Ca^{2+}$  plus calcium-thromboplastin will form a clot. The process of clot formation is detected as a electromagnetic clot by the detector. Presentation of the results in the form of INR was performed by means of the calculation results PPT

patients which were divided by mean normal plasma then raised to the value of the International Sensitivity Index (ISI) with the normal value of 0.8 to 1.2.

Analysis was conducted to test the validity of analytical precision compute averages, Standard Deviations (SD) and the Coefficient of Variation (CV). Accuracy test was conducted by test recovery. Characteristics of research subjects were displayed descriptively in proportion. Characteristics of the laboratory results were presented in mean, standard deviations, median (minimum-maximum). The correlation between serum levels of MMP-1 by the MELD score was tested by Pearson correlation test. Statistical calculations using a significance of p<0.05.

## **RESULTS AND DISCUSSION**

In this study, patients with hepatic cirrhosis as many as 30 persons with an average age of 52.43 years and most were males in 19 patients (63.3%).

A research conducted by Chuan Lee *et al.*<sup>14</sup> showed similarities with this study, the mean age of patients with hepatic cirrhosis was 54 years of age, patients were more males than females and the alleged most common cause was the hepatitis B virus.<sup>14</sup> The study by

Variables	Frequency n=30	Proportion (%)	
Age (years)	52,43±14,75	_	
Gender			
Male	19	63.3	
Female	11	36.7	
Causes of hepatic cirrhosis			
Hepatitis B virus	18	60.4	
cholestasis	10	33	
Drug induced	1	3.3	
Not known	1	3.3	

**Table 1.** Basic characteristics of the research subject

Table 2. The Laboratory result of hepatic cirrhosis and MELD score

Variables	Mean ±SD/Median (min-max)
MMP-1 ( $\mu$ g/mL) (mean±SD)	106.91±59.78
MELD Score (median, min-max)	15.5 (7–35)
Creatinin (mg/dL) (median, min-max)	0.89 (0.45–23)
Bilirubin (mg/dL) (median, min-max)	2.56 (0.66–25.86)
International Normalized Ratio (median, min-max)	1.27 (0.76–2.68)



Figure 1. Correlation of serum levels of MMP-1 against the MELD score

Pleli *et al.*<sup>15</sup> with the results of hepatic cirrhosis patients with a mean age of 58 years, males more than females, with the most common cause was alcoholism. In alcoholic hepatic fibrosis was due to the accumulation of free radicals such as superoxide.<sup>15</sup>

Another study conducted by Gheorghe *et al.*<sup>5</sup> in patients with end stage hepatic disease undergoing hepatic transplantation obtained at a mean age of 45 years, most were males with the most cause of hepatitis virus.<sup>5</sup> A similar study conducted by Ghadir *et al.*<sup>16</sup> with ages between 41 and 50 years, more males than females and as the most common cause of HBV.<sup>16</sup> A research was conducted Dultz *et al.*<sup>17</sup> in patients with chronic hepatitis, mean age 51 years, males more than females.<sup>17</sup>

A research conducted by Chuan Lee *et al.*<sup>14</sup> showed that MELD score was 12, the mean bilirubin level was 2.1 mg/dL, the mean serum creatinine level was 1.1 mg/dL, mean INR value is  $1.2.^{14}$ 

A research by Pleli *et al.*<sup>15</sup> found that the median MELD score was 14, creatinine levels of 1.03 mg/dL, INR value of 1.35 and a bilirubin level of 1.9 mg/dL.<sup>15</sup>

A research conducted Dultz *et al.*<sup>17</sup> in patients with chronic hepatitis, the mean value of MELD score was 9, the bilirubin levels of 1.12 mg/dL, INR value of 1.19 and a serum creatinine level of 0.84 mg/dL.<sup>17</sup> A research conducted by Moore *et al.*<sup>18</sup> stated that the higher the MELD score had an increased risk of death within 90 days. Patients with a MELD score <15 were less useful for a hepatic transplant.<sup>18</sup>

This research obtained a moderate and significant negative correlation between the levels of MMP-1 by the MELD score, with a value of r=-0.402 and p=0.028 (Figure 1).

A research conducted by Adel *et al.*<sup>19</sup> suggested that the serum levels of MMP-1 had a negative correlation with the degree of fibrosis.<sup>19</sup>

Limitations of this study were that did not checked the serial and the subjectivity of the examiner to look at the patient's clinical signs. In addition, this study had limitations in participating in the clinical assessment of patients, cirrhotic patients for clinical assessment including clinical factors constituent MELD score was left entirely to the clinician colleagues in the Department of Internal Medicine Dr. Sardjito Hospital.

### **CONCLUSIONS AND SUGGESTIONS**

In this study there was moderate and significant negative correlation between serum levels of MMP-1 by the MELD score in patients with hepatic cirrhosis. For clinical applications, examination of serum MMP-1 can be used to monitor disease progression and treatment outcomes of patients with hepatic cirrhosis.

## REFERENCES

- WHO. Viral Hepatitis in the WHO South-East Asia Region. Regional Office for South-East Asia, New Delhi. WHO, 2011; 1-15. Available from: hepcasia.com/wp-content/ upload/2015/03/WHO\_searo\_viral\_hepatitis-report pdf.
- Nurdjanah S, Sudoyo AW, Setiyohadi B, Alwi I, M. Simadibrata, Setiati S. Textbook of Medicine. Volume 1, issue V. Jakarta, Publishing Center Department of Medicine Faculty of Medicine, University of Indonesia, 2009; 668–673.
- K. Walsh, Alexander G.J.M. Update on chronic viral hepatitis, Postgrad.Med.J. 2001; 910: 498–505.
- 4. Friedman S.L. Liver fibrosis from bench to bedside, J. Hepatol. 2003; 38(81): 538–53.
- Gheorghe L, Iacob S, R. Iacob, Gheorghe C, Popescu I. Variation of the MELD Score as a predictor of death on the waiting list for liver transplantation. A gastrointestinal Liver Dis. 2007; 16(3): 267–272.
- Botta F, Giannini E, P. Romagnoli, Fasoli A, F. Malfatti, Chiarbonello B, E. Testa, D. Risso, Colla G, Testa R. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with the residual liver function: a European study, Gut 2003; 52: 134–139.
- Bataller R, Brenner DA. A Miscellaneous, Overview of Liver Fibrosis, Textbook of Gastroenterology. Fifth Ed., Oxford, England, Blackwell Publishing. 2009; 658–679.
- E. Giannini, Botta F, E. Testa, P. Romagnoli, Polegato S., Malfatti, Fumagagalli, Chiarbonello B., D. Risso, Testa R. The 1-year and 3-month prognostic utility of the AST/ALT ratio and the model for end-stage liver disease score in patients with viral liver cirrhosis. AMJ Gastroentero 2002; 97(11): 2855–60.

- 9. K. Neubauer, B. Saile, Ramadori G. Altered Liver fibrosis and matrix synthesis. Can J Gastroenterol. 2001; 15(3): 187–193.
- S.A. Gunnarsdóttir Liver cirrhosis-Epidemiological and Clinical Aspects.anna.gunnarsdottir@medic.gu.se, reproservice Chalmers, Göteborg Department of Internal Medicine, The Sahlgrenska Academy at Göteborg University, Sweden, in 2008.
- Wynn TA. Regulate Common and unique mechanisms of fibrosis in various fibroproliferative diseases. J Clin Invest. 2007; 117(3): 524–29.
- 12. Sternlicht MD, Werb Z. How metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17: 463–516.
- K. Okamoto, K. Mimura, Murawaki Y, and Yuasa I. Association of functional gene polymorphisms of matrix metalloproteinase (MMP) -1, MMP-3 and MMP-9 with the progression of chronic liver disease. JGH 2005; 20(77): 1102–1108.
- 14. Chuan Lee K, Y. Ying Yang, Wen Wang Y, Lee F. Yauh, Chuan Loong C, M. Hou Chih, Chieh Lin H, Dong Lee S. Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxins and portal pressure. Dig Dis Sci.2010; 55: 2077–2085.
- 15. Pleli T, Martin D, Kronenberger B, F. Brunner, Koberle V, G. Grammatikes, Farnik H, Y. Martinez, F. Finkelmeier, Labocha S, N. Ferreiros, Zeuzem S, Albrecht P, O. Waidmann. Autotaxin Serum is a parameter for the severity of liver cirrhosis and overall survival in Patients with liver cirrhosis A Prospective Cohort Study. PLoS One, 2014; 9(7): 1–9.
- Ghadir MH, Riahin AA, Havaspour A, Nooranipour M, Habibinejad AA. The Relationship between lipid profile and severity of liver damage in cirrhotic Patients. Hepat Mon. 2010; 10(4): 285–288.
- G. Dultz, Seelhof M, E. Herrmann, Welker MW, Rust MF, Teuber G, B. Kronenberger, Von Magner M, Vermehren J, C. Sarrazin, Zeuzem S, Hoffman WP. Baseline MELD Score Predicts hepatic decompensation during antiviral therapy in Patients with chronic hepatitis C and advanced cirrhosis.PLOS ONE, 2013; 8(8): 1–6.
- Moore CM, George M, Lateef O, Van Thiel DH. The MELD Score: Limitations and Consequences. Wseas Transactions on Biology and Biomedicine, 2012; 2(9): 55–65.
- Adel AM, Amal SB, Sherif SS. Serum TGF beta, serum MMP-1 and HOMA-IR as a non-invasive predictors of fibrosis in Egyptian patients with NAFLD. Saudi Journal of Gastroenterology 2012; 15(3) 190–195.